All > Liver Fibrosis > Meningioma

Bevacizumab for Recurrent Meningiomas

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Recurrent Meningiomas+5 MoreBevacizumab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the addition of bevacizumab to Optune improves meningioma control.

Eligible Conditions
  • Recurrent Meningiomas
  • Malignant Meningioma
  • Supratentorial Meningioma
  • Atypical Meningioma
  • Grade II Meningioma
  • Grade III Meningioma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Bevacizumab
1
BI 905711
1
Bevacizumab

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: From time of registration to death, assessed up to 2 years

At 6 months
Progression Free Survival for 6 months (PFS-6)
Month 12
Tumor Response Rate (TRR)
Month 1
Quality of Life (QOL) with treatment using FACT-Br questionnaire
Year 2
Overall Survival (OS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Bevacizumab
1
BI 905711
1
Bevacizumab

Side Effects for

Bevacizumab
22%vitreous hemorrhage
17%worsening of cataract
9%vitreous syneresis
9%posterior capsule opacification
4%pyelonephritis
4%pneumonia
4%colon cancer
4%cranial nerve VI palsy
4%bradycardia
This histogram enumerates side effects from a completed 2015 Phase 4 trial (NCT02036424) in the Bevacizumab ARM group. Side effects include: vitreous hemorrhage with 22%, worsening of cataract with 17%, vitreous syneresis with 9%, posterior capsule opacification with 9%, pyelonephritis with 4%.

Trial Design

1 Treatment Group

Treatment (bevacizumab, electric field therapy)
1 of 1

Experimental Treatment

27 Total Participants · 1 Treatment Group

Primary Treatment: Bevacizumab · No Placebo Group · Phase 2

Treatment (bevacizumab, electric field therapy)Experimental Group · 4 Interventions: Bevacizumab, NovoTTF-200A Device, Electric Field Therapy, Quality-of-Life Assessment · Intervention Types: Biological, Device, Procedure, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
FDA approved
Quality-of-Life Assessment
2016
Completed Phase 3
~7220

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from time of registration to death, assessed up to 2 years

Who is running the clinical trial?

NovoCure Ltd.Industry Sponsor
53 Previous Clinical Trials
4,567 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,070 Previous Clinical Trials
41,129,087 Total Patients Enrolled
3 Trials studying Recurrent Meningiomas
180 Patients Enrolled for Recurrent Meningiomas
Northwestern UniversityLead Sponsor
1,447 Previous Clinical Trials
777,225 Total Patients Enrolled
Priya Kumthekar, MDPrincipal InvestigatorNorthwestern University
3 Previous Clinical Trials
98 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top